Navigation Links
Upcoming in Medical Technology

Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting

SEATTLE, April 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) announced today that it will present data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver, April 1...

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it has been selected to present the results from the study, entitled, "Open Label Study to Assess the Safety, Pharma...

Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences

RICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business ...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, Californi...

Genmab Announces Upcoming Ofatumumab Studies

Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies Planned COPENHAGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. ...

Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today that company representatives are givi...

Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP ), an innovator in the discovery and development of novel small molecule therapeutics, announced today that results from the company's Phase 2a clinical trial evaluating PS433540, its first-in-class Dual Acting Rec...

Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings

SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetings over the coming months. These presentations will highlig...

Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences

NEW BRUNSWICK, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today that Dr. Raghavendra Mirmira, one of the Company's funded researchers, will be presenting his findings regarding preclinical pancreatic islet cell ...

CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting

BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that updated preliminary clinical trial results from the Phase II study ...

IDM Pharma Announces Upcoming Clinical Data Presentations

IRVINE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI ), a biotechnology company focused on the development of innovative cancer therapies, today announced details on clinical data presentations evaluating three of the Company's pipeline compounds to be presented at...

Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference

SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Th...

Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that the company is scheduled to provide a corporate overview of its clinical development and discovery programs at four upcoming investor conferences: -- ThinkEquity Partners' 5th Annua...

ViroPharma to Present at Three Upcoming Healthcare Conferences

EXTON, Pa., Aug. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that Vincent Milano, vice-president, chief operating officer and chief financial officer of ViroPharma, will present at the Thomas Weisel Partners 2007 Healthcare Conference at 8:00 A.M. ET o...

New Clinical Data for Cytogen's Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 26, 2007 - Cytogen Corporation (NASDAQ: CYTO) today announced that five abstracts will be presented or published at upcoming major medical meetings. The data will include various Phase 1 clinical results for QUADRAMET(R) (samarium Sm-153 lexidronam injection) i...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated announced data will be presented on the Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the American ...

CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that posters related to its oncology research efforts will be presented at the 98th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007 in Los Angeles, CA. "Sys...

Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action

EXTON, Pa.--(BUSINESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals, Inc. today announced that Dr. Shaker Mousa, Professor of Pharmacology and Executive Vice President and Chairman of the Pharmaceutical Research Institute at Albany College of Pharmacy, will present new preclinical data detailing the...

CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings

BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation and TopoTarget A/S announced today that preliminary interim clinical data on intravenous belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, are expected to be pres...

FDA Announces Change of Location Notice for Upcoming Advisory Committee Meeting

ROCKVILLE, Md., April 18, 2007--Due to water damage caused by flooding over the weekend, FDA has been forced to change the location for the upcoming Antiviral Drugs Advisory Committee meeting on April 24, 2007 to discuss new drug application for maraviroc 300 milligram tablets. Originally schedule...

Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) and the Company's clinical collaborators will report updated Phase 2 clinical trial results for its lead cancer therapy product candidates at the upcoming annual meetings of The American Society of Clinical Onc...

Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that data from its randomized, blinded, placebo-controlled phase 2 clinical trials of CRx-102 in patients with osteoarthritis (OA) and rheumatoid arthritis (RA) will be featured at the Europea...

Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that detailed results from the Company's recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at a series of upcoming U.S. urology meeti...

Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings

HASBROUCK HEIGHTS, NJ (June 21, 2007) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that detailed results from the Company’s recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at a series of upcoming U.S. urology meetings, beginni...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that abstracts related to Sulonex(TM) (sulodexide oral gelcap) have been selected for publication or presentation during the poster sessions scheduled to take place at the upcoming American Diabetes As...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...ontaining activating KRAS mutations." Detailed efficacy and safety data according to KRAS status will be submitted for presentation at an upcoming medical congress. Study Design PRIME ( P anitumumab R andomized trial I n combination with chemotherapy for M etastatic colorec...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... us to continue to advance the technology and fill the pipeline with more exciting new drugs," said B. Lynne Parshall, COO and CFO of Isis. upcoming Key Milestones Report full data from a Phase 3 study evaluating mipomersen in homozygous Familial Hypercholesterolemia (FH) patients; p...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

...lf that of Forteo(R) in the highest dose of BA058 tested. Radius will submit additional detailed results from the Phase 2 study for presentation at an upcoming medical meeting. "The results of this study affirm BA058's safety and bone-building activity and support its promise as a next-generation anabo...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...t in a number of serious bone complications, collectively called SREs. Full safety and efficacy data will be submitted for presentation at an upcoming medical meeting in the second half of this year. Study Design This was an international Phase 3, randomized, doubleblind, active controlle...

John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden

...at artists to come together to powerfully and effectively fight AIDS in Africa," said Legend. "I'm proud to be partnering with Gap and (RED)(TM) on my upcoming Madison Square Garden concert, because I know the money generated will go directly to help get medicine to those who need it." Tickets to this ...

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

...es of the study data, including secondary efficacy endpoints and detailed safety is underway. Additional data will be submitted for presentation at an upcoming medical meeting. "The clinical outcomes of these Phase 3 studies are important, especially during the declared influenza pandemic, as they ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

...esult in a number of serious bone complications, collectively called SREs. Full efficacy and safety data will be submitted for presentation at an upcoming medical meeting in the second half of this year. Study Design This was an international Phase 3, randomized, double-blind study comparing d...

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

...model of aggressive arthritis. These data were published in the June 14, 2009 online edition of Nature Medicine and will be published in the upcoming July 2009 print edition in an article titled: A Selective Inhibitor of the Immunoproteasome Subunit LMP7 Blocks Cytokine Production and Attenuates Pr...

Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009

... biomedical, health care and life science professionals from all over the world," said Nadav Kidron, Oramed CEO. For more information about the upcoming ILSI Biomed conference, please visit http://www2.kenes.com/biomed/Pages/Home.aspx About Oramed Pharmaceuticals Oramed Pharmaceuticals ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

...and the FDA reached agreement on the design of the upcoming Phase 3 study via the Special Protocol Assessment ...data from the prior Phase 3 study of orBec(R), the upcoming confirmatory Phase 3 clinical trial will be a high...response from the EMEA regarding the design of our upcoming confirmatory, pivotal Phase 3 study," stated Chris...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

...rgery (CABG). Since the BARI-2D study enrolled a very small subset of CAD patients with diabetes, SCAI looks forward to additional data from the upcoming FREEDOM trial, which may shed more light on revascularization options for this growing patient population. What BARI-2D Demonstrates About Pat...

Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

...actory Angina Due to Diffuse Coronary Heart Disease", reinforce the company's regulatory strategy of submitting an IDE for its PHOENIX System in the upcoming months." About Cardiogenesis Corporation Cardiogenesis is a medical device company specializing in the therapies for the treatment of chroni...

Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections

... factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics. Members of the media are welcome to attend our upcoming webinar entitled Hospital Anti-Infectives Insight Series: Analyzing Prescribing Trends and Emerging Therapies in the Hospital Antibiotic Market. T...

VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction

...uding results from two phase 3 obesity trials of our lead product Qnexa as well as data from the REVIVE trial of avanafil and participation in several upcoming medical meetings." About VIVUS VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet...

HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials

...ich was reviewed and approved by the leadership of the five networks, recommending the use of the Abbott RealTi m e HIV-1 assay and m 2000 system for upcoming clinical trials in 2009 and beyond that have a primary focus on viral load measurements. The recommendation applies to testing performed at adult and ...
Other Tags
(Date:7/9/2014)... Sexual selection refers to species, selection for traits that ... of natural selection enhances opportunities to mate, the tail ... at the University of California, Riverside have now found ... a placenta are linked. Describing the life histories ... family Poeciliidae, the researchers found that species with placentas ...
(Date:7/9/2014)... (TCGA) Research Network have identified novel mutations in ... most common subtype of lung cancer. Knowledge of ... possible therapeutic targets for this disease and potentially ... mutations because many potent cancer drugs that target ... funded and managed by the National Cancer Institute ...
(Date:7/9/2014)... With grilling season upon us, many backyard cooks are ... fatty hot dogs. But low fat can sometimes mean ... addressing the texture problem in low-fat wieners that are ... study was published in ACS, Journal of Agricultural ... colleagues note that hot-dog consumers have come to expect ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
(Date:7/9/2014)... The liver is one of the most important organs ... that we utilize our food properly this is ... removed from our organism this is its detoxification ... and unhealthy food all damage the liver. The resulting ... deposits, cirrhoses, and life-threatening liver failure. According to the ...
(Date:7/9/2014)... studies linking older age with kidney and heart disease ... donation among older adults. However, in the first study ... Perelman School of Medicine at the University of Pennsylvania ... enjoy similar life expectancy and cardiovascular health as very ... In light of the ever increasing organ transplant waitlists, ...
(Date:7/9/2014)... has risen dramatically in Western societies. One frequently cited ... and have fewer infections than previous generations, thereby delaying ... researchers at Sahlgrenska Academy, University of Gothenburg, monitored children ... the immune system in relation to allergic disease. All ... Vstra Gtaland Region, half of them on farms that ...
(Date:7/8/2014)... awarded up to $15 million by the Defense Advanced ... aiming to help brain-injured people restore lost memory functions. ... psychology and physics will collaborate to create, surgically implant, ... Memory is the process in which neurons in certain ... retrieve it. Certain types of illnesses and injuries disrupt ...
(Date:7/8/2014)... found to be three times higher when auditors were ... auditors present, according to a study in a major ... "Quantification of the Hawthorne effect in hand hygiene compliance ... study," published today on-line in the BMJ Quality ... Srigley, who did the study as part of her ...
Breaking Medicine News(10 mins):Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3
Other Contents